The efficacy and safety of betamethasone dipropionate, 0.05% in a propylene glycol base (Diprolene), was investigated in an open, fixed-dose study of thirty-one patients with resistant psoriasis. Clearing of lesions or marked improvement occurred in 97% (thirty out of thirty-one) of patients. Increased penetration of corticosteroid did not cause adrenal suppression or other adverse reactions.
Get full access to this article
View all access options for this article.
References
1.
CharneyP (1976) Betamethasone dipropionate cream for the treatment of psoriasis. Archives of Dermatology112, 681.
2.
DownieD A W (1978) The effect of betamethasone dipropionate cream 0.05% (Diprosone) on adrenocortical function. Australian Journal of Dermatology19, 114.
3.
FeimelM (1969) Effect of potent topical steroids on plasmacortisol levels of infants and children with eczema. Lancet1, 485.
4.
GillK ABaxterD L (1964) Plasma Cortisol suppression by steriod creams. Archives of Dermatology89, 734.
5.
MarchC (1965) Adrenal function after topical steroid therapy. Clinical Pharmacology and Therapeutics6, 43.
6.
McKenzieA WAtkinsonR M (1964) Topical activities of betamethasone esters in man. Archives of Dermatology89, 741.
7.
McKenzieA WStoughtonR B (1962) Method for comparing percutaneous absorption of steroids. Archives of Dermatology86, 608.
8.
ScogginsR BKlimanB (1965) Percutaneous absorption of corticosteroids – systemic effects. New England Journal of Medicine273, 831.
9.
ShelmireJ B J (1960) Factors determining the skin-drug-vehicle relationship. Archives of Dermatology82, 24.
10.
WilsonJ GWarkangJ (1965) Teratology – Principles and Techniques. Univ. of Chicago Press, Chicago. p. 204.
